9 Reasons Your Eyebrows and Eyelashes Are Thinning in Menopause — and Which Ones Need Medical Attention
The outer-third eyebrow thing really got to me — not because of vanity, but because nobody warned me it was coming and nobody mentioned it might mean something. When it turned out my thyroid needed attention on top of the estrogen drop, I was genuinely glad I pushed for the blood panel instead of just buying a brow pencil.
Learn more about Rose →Estrogen Withdrawal Shrinks Hair Follicles Across the Face
Estrogen prolongs the anagen (active growth) phase of the hair cycle, so when levels fall sharply during perimenopause and menopause, follicles across the scalp, brows, and lash line shift prematurely into the resting phase. The result is shorter, finer hairs that fall out before they reach visible length. This process is diffuse — it affects the whole follicle field rather than creating the patchy or outer-third loss that other causes produce.
Androgen-Driven Follicle Miniaturization Thins the Outer Brow
As estrogen falls, the relative influence of androgens — including testosterone and its more potent derivative DHT — increases, even when absolute androgen levels stay the same. DHT binds to follicle receptors in genetically susceptible areas and progressively miniaturizes them, producing the classic thinning of the lateral (outer) third of the eyebrow. This is physiologically identical to the mechanism behind female-pattern scalp hair loss and requires a different approach than simple hormone replacement.
Hypothyroidism Is the Most Important Overlap Condition to Rule Out
Thyroid hormone is essential for initiating and sustaining the anagen phase in follicles, and hypothyroidism — which becomes significantly more common in the same demographic as perimenopause — causes diffuse thinning of both eyebrows and eyelashes, often with pronounced loss at the outer brow. Because symptoms of hypothyroidism (fatigue, cold sensitivity, brain fog, weight change) overlap heavily with perimenopause symptoms, thyroid dysfunction is frequently missed or attributed to hormones. A TSH blood test is the standard first step and is worth requesting proactively if brow and lash thinning is notable.
Alopecia Areata Produces Patchy Loss That Looks Different from Hormonal Thinning
Alopecia areata is an autoimmune condition in which immune cells attack hair follicles, and it can affect brows and lashes independently of scalp hair. The pattern is typically patchy — a defined oval or strip of absent hair rather than the gradual diffuse thinning seen with hormones — and may appear or worsen during the hormonal volatility of perimenopause, since estrogen has known immunomodulatory effects. This distinction matters because alopecia areata warrants dermatological assessment and has specific treatment pathways including topical immunosuppressants and, more recently, JAK inhibitor medications.
Iron Deficiency Starves Follicles of the Fuel They Need to Grow
Ferritin — the stored form of iron — is a critical cofactor for the enzyme ribonucleotide reductase, which drives cell proliferation in the hair matrix. Low ferritin (even when hemoglobin remains technically normal) is consistently associated with diffuse hair loss including brow thinning, and perimenopause-era women are particularly vulnerable if heavy perimenopausal bleeding has depleted stores. A serum ferritin test is the relevant marker; a standard hemoglobin or iron panel alone will not catch this.
Protein Restriction or Crash Dieting Triggers Telogen Effluvium in Brows and Lashes
Follicles are metabolically expensive structures, and when caloric or protein intake drops sharply — whether from deliberate dieting, illness, or stress — the body deprioritizes hair growth and pushes follicles into the telogen (resting) phase. This diffuse shedding, called telogen effluvium, typically appears two to four months after the dietary trigger and can affect brows and lashes as well as scalp hair. The pattern resolves once adequate nutrition is restored, but the lag between cause and visible loss makes the connection easy to miss.
Biotin Deficiency Is Real but Far Rarer Than Supplement Marketing Implies
Biotin (vitamin B7) is genuinely necessary for keratin synthesis, and clinical deficiency does cause hair and brow loss — but true biotin deficiency is uncommon in women eating a varied diet. What is more relevant is that high-dose biotin supplementation, which is widely marketed for hair loss, can interfere with thyroid blood test results (TSH and T4), potentially masking or mimicking thyroid dysfunction. Women taking biotin supplements who are also being investigated for brow thinning should pause supplementation for at least 48 hours before any thyroid panel.
Chronic Stress Elevates Cortisol in Ways That Directly Suppress Hair Follicle Activity
Sustained psychological or physiological stress elevates cortisol, which has been shown in human follicle tissue studies to reduce the expression of key growth factors including IGF-1 and to push follicles prematurely into catagen (regression). The perimenopause years frequently coincide with peak life-stressor load — aging parents, career transitions, relationship changes — meaning stress-induced follicle suppression compounds the hormonal effect. The mechanism is distinct from simple aging and is at least partially reversible with stress reduction, though no large RCTs have tested this specifically for brow and lash follicles.
Some Medications Commonly Prescribed in Menopause and Midlife Cause Follicle Loss as a Side Effect
Several medications with high midlife prescription rates — including certain antidepressants (SSRIs and SNRIs), blood pressure medications (particularly beta-blockers), cholesterol-lowering statins, and anti-anxiety agents — list hair loss as a recognized side effect, with mechanisms ranging from telogen effluvium to direct follicle toxicity. Because brows and lashes receive less clinical attention than scalp hair, drug-induced loss in these areas is frequently overlooked. Any woman who notices brow or lash thinning that began within three to four months of starting a new medication should raise this timeline explicitly with her prescriber rather than assuming it is hormonal.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.